Ramadan is a holy month of fasting, prayer, and reflection observed by millions of Muslims around the world. It is a time for spiritual growth and self-discipline and is one of the five pillars of Islam. Ramadan is a month-long observance in Islam whereby Muslims fast from dawn until sunset. Here are some things to know about Ramadan:
• Fasting happens during daylight hours
Ramadan is based on the lunar calendar and begins with hilal, which is the Arabic word for crescent or “new moon”. This happens in the ninth month of each lunar year. But because the lunar cycle steadily moves backwards, Ramadan falls earlier and earlier each year – moving back 11 days each time. During the month of Ramadan, Muslims fast from dawn until sunset. This means abstaining from food, drink, smoking, and other pleasures during daylight hours. This can be especially challenging during the summer months when the days are longer and hotter.
• There are two main meals eaten during Ramadan
During Ramadan, Muslims eat two main meals each day: suhoor and iftar. Suhoor is eaten before dawn and is meant to provide energy for the day ahead. Iftar is eaten after sunset and marks the breaking of the fast. It is important to eat nutritious, energy-rich foods during suhoor and iftar to help sustain the body during the fasting hours.
• Dates are traditionally the first thing eaten at iftar
In adherence to how the Islamic prophet Muhammad broke his fast, a handful of dates followed by a glass of water are consumed before Maghrib (evening prayer) and the main meal. Soaking dates in milk overnight is a Middle Eastern iftar favourite. Some would eat dates followed by fruit or yogurt, which helps to kick-start the body’s metabolism after a day’s worth of fasting.
• Hunger-busting drinks are a big thing during Ramadan
Staying hydrated is essential during Ramadan, especially during the long fasting hours. In addition to water, there are many thirst-quenching beverages that are popular during Ramadan. For example, in the Middle East, jallab is a sweet drink made from dates, rosewater, and carob, usually served with pine nuts and raisins. Khoshaf is another sweet treat made of boiled dried fruits like apricots, plums, figs, dates, and raisins and flavoured with rosewater. Malaysia and Singapore have millennial-pink bandung, which is a rosewater-flavoured milky drink. Smoothies are also a popular way to rehydrate and get essential nutrients.
• Fasting during Ramadan is a must, but there are ‘loopholes’
Although fasting during Ramadan is mandatory for all healthy adult Muslims, there are some exceptions. Those who are unwell and/or taking medication, elderly, travelling, pregnant or breastfeeding, as well as children under the age of puberty, can forgo fasting – especially if it will negatively impact their health. A fast can also be broken if a woman is on her period. In all these cases, those who broke their fast can make up for the missed days of fasting.
• Ramadan is notorious for being a month of weight gain
Despite the daily fasting, many people gain weight during Ramadan. This is because the low activity levels during the day often give way to binge eating at night, which can result in slower metabolic cycles that may cause the body to store fat instead of burning it. In order to maintain a healthy weight throughout the month, Muslims are encouraged to drink plenty of water, eat a diet full of fruits, vegetables, and protein, and wake up every morning for suhoor.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.